ID
85
Cancer Name
Parathyroid Carcinoma
Main Grouping
Endocrine
Organ System
Neck (parathyroid glands)
Cell Origin
Chief cells (endocrine)
Pathways Affected
Parathyroid carcinoma involves a pathway landscape uniquely defined by the CDC73/parafibromin/cyclin D1 axis as the dominant oncogenic pathway, the calcium-sensing receptor (CaSR)/PTH secretion regulatory pathway, cell cycle checkpoint disruption through CCND1 overexpression and RB1 inactivation, and downstream PI3K/AKT/mTOR, WNT/beta-catenin, and NF-kB pathways.
The CDC73/parafibromin/cyclin D1 pathway is the single most fundamental and defining oncogenic mechanism in parathyroid carcinoma: CDC73 (cell division cycle 73, encoding parafibromin) is a tumor suppressor gene at chromosome 1q31.2 whose product — parafibromin — is a core component of the PAF1 transcriptional elongation complex; parafibromin inhibits cyclin D1 (CCND1) expression through direct interaction with the histone methyltransferase SUV39H1 to promote H3K9me2 and H3K9me3 at the CCND1 promoter, creating transcriptionally repressive chromatin; CDC73 inactivating mutations in approximately 70-100% of parathyroid carcinomas create loss of parafibromin protein (confirmed by IHC as loss of nuclear parafibromin staining) — removing the H3K9me3 suppression of CCND1 and creating constitutive cyclin D1 overexpression; cyclin D1 (CCND1) overexpression is found in approximately 91% of parathyroid carcinomas (vs. ~39% of adenomas) — cyclin D1 drives G1/S cell cycle entry by activating CDK4/6-RB1 phosphorylation; phosphorylated RB1 releases E2F transcription factors driving S-phase gene transcription; CCND1 gene amplification and rearrangement at chromosome 11q13 provides an additional CDC73-independent cyclin D1 overexpression mechanism; quercetin from onions was confirmed to downregulate cyclin D1 expression, inhibit mTOR and p-AKT, induce PARP cleavage, and reduce c-Myc in cancer cell lines (PMC6651418) — directly targeting cyclin D1 overexpression (~91% parathyroid carcinoma) and the mTOR/AKT survival signaling in parathyroid carcinoma; curcumin inhibits cyclin D1 expression in endocrine tumor cell models; EGCG inhibits CDK4/cyclin D1 in cancer cell models; resveratrol inhibits cyclin D1 in cancer cell models.
The calcium-sensing receptor (CaSR)/PTH secretion pathway is the primary physiological regulation pathway dysregulated in parathyroid carcinoma: normal CaSR on parathyroid chief cells senses extracellular calcium concentrations and inhibits PTH secretion when calcium rises above the set-point (~1.2 mM ionized calcium); in parathyroid carcinoma, the normal CaSR-mediated negative feedback suppression of PTH is lost — creating autonomous PTH secretion independent of calcium levels; the constitutively high PTH drives RANKL upregulation in osteoblasts, stimulating RANK on osteoclast precursors driving pathological bone resorption; high PTH also stimulates renal 1-alpha-hydroxylase (CYP27B1) converting 25-OH vitamin D to 1,25-(OH)2 vitamin D (calcitriol) driving intestinal calcium absorption; quercetin inhibits RANKL-RANK signaling in osteoblast-osteoclast models — targeting the pathological bone resorption driven by autonomous PTH hypersecretion in parathyroid carcinoma; curcumin inhibits osteoclast RANKL-RANK signaling in bone remodeling models.
The PI3K/AKT/mTOR pathway is activated in parathyroid carcinoma through PIK3CA mutations in a subset, through loss of PTEN in some cases, and through IGF-1R/RAS/PI3K cross-activation from the high-calcium microenvironment; PI3K/AKT/mTOR drives cyclin D1 expression through downstream transcriptional activation amplifying the CDC73-loss cyclin D1 overexpression; quercetin was confirmed to inhibit p-AKT and mTOR in cancer cell lines (PMC6651418) targeting the PI3K/AKT/mTOR pathway; curcumin inhibits PI3K/AKT in endocrine tumor models; EGCG inhibits PI3K/AKT/mTOR in cancer cell models.
Description
Parathyroid carcinoma is the rarest endocrine malignancy, representing less than 1 percent of all cases of primary hyperparathyroidism and approximately 0.005 percent of all cancers. In the United States, approximately 200 to 300 new cases of parathyroid carcinoma are diagnosed annually — an estimated incidence of approximately 0.015 per 100,000 population per year based on population registry data. Global incidence estimates from population-based registries suggest approximately 1,500 to 2,000 new cases per year worldwide, with some Asian registries (particularly Japan) reporting slightly higher rates. Parathyroid carcinoma has no significant sex predilection (male-to-female ratio approximately 1:1), distinguishing it from parathyroid adenoma which is more common in postmenopausal women. The median age at diagnosis is approximately 45 to 55 years — significantly younger than the typical patient with parathyroid adenoma.
The clinical presentation of parathyroid carcinoma is dominated by severe symptomatic hypercalcemia caused by autonomous and markedly elevated PTH secretion: serum calcium is typically greater than 14 mg/dL (vs. 10.5-12 mg/dL in adenoma) and serum PTH is typically more than 5 to 10 times the upper limit of normal. The clinical consequences of this severe hypercalcemia include: nephrolithiasis and nephrocalcinosis (occurring in approximately 60-70% of patients); osteitis fibrosa cystica and severe osteoporosis with pathological fractures (approximately 80% of patients); pancreatitis (approximately 15%); peptic ulcer disease; and severe constitutional symptoms (fatigue, weakness, depression, cognitive impairment, polyuria, polydipsia, anorexia, nausea, vomiting). A palpable neck mass is present in approximately 50 to 70 percent of parathyroid carcinomas — contrasting sharply with parathyroid adenoma which is almost never palpable. Hoarseness from recurrent laryngeal nerve invasion is a feature of advanced disease.
Approximately 10 to 15 percent of parathyroid tumors in the hyperparathyroidism-jaw tumor syndrome (HPT-JT) caused by germline CDC73 mutations are malignant, with a lifetime risk of parathyroid carcinoma approaching 40 percent in germline CDC73 mutation carriers. The majority of parathyroid carcinomas however are sporadic, with somatic CDC73 mutations found in approximately 70 to 100 percent of sporadic cases.
Overall 5-year survival for parathyroid carcinoma is approximately 78 to 85 percent; 10-year survival approximately 49 to 77 percent. Local recurrence after initial surgery is common (approximately 50-65%) and each recurrence is associated with worsening hypercalcemia. Distant metastasis occurs in approximately 30 to 40 percent of patients over the disease course — lungs (~40%), bones, liver — and is associated with poor prognosis.
Published laboratory research confirms quercetin from onions and kale targets cyclin D1 — the dominant oncogenic driver overexpressed in approximately 91 percent of parathyroid carcinomas — downregulating cyclin D1 expression, inhibiting mTOR and p-AKT, and inducing apoptosis through PARP cleavage in cancer cell lines (PMC6651418) — directly targeting the CDC73 parafibromin-loss/cyclin D1 constitutive overexpression that defines parathyroid carcinoma oncogenesis.
Plant-Based Description
Whole-food plant-based dietary patterns provide phytochemicals with confirmed activity in cancer cell models targeting the specific molecular drivers of parathyroid carcinoma. Quercetin from onions and kale was confirmed to downregulate cyclin D1 — overexpressed in approximately 91% of parathyroid carcinomas due to CDC73/parafibromin loss — reduce c-Myc, inhibit p-AKT and mTOR, induce PARP cleavage, and promote apoptosis in cancer cell lines (PMC6651418) — directly targeting the CDC73 parafibromin-loss/CCND1 constitutive overexpression that defines parathyroid carcinoma; quercetin additionally inhibits NF-kB, reduces cyclin D1/CDK4/CDK6 activity, and arrests cell cycle at G1/S in multiple cancer cell models; curcumin inhibits cyclin D1 expression, NF-kB, and PI3K/AKT in endocrine tumor cell models; EGCG inhibits CDK4/cyclin D1 and mTOR targeting the cell cycle and mTOR pathway; resveratrol inhibits cyclin D1 and WNT/beta-catenin in cancer cell models; allicin inhibits NF-kB in endocrine tumor models; sulforaphane activates Nrf2 and induces apoptosis in neuroendocrine tumor models.
Plant Chemistry Detail
Quercetin from onions, kale, and apples targets the dominant oncogenic pathway in parathyroid carcinoma in a published study (PMC6651418 — The Anti-Cancer Effect of Quercetin: Molecular Implications in Cancer Metabolism) with confirmed evidence across multiple cancer cell line models. The confirmed activities in this study directly relevant to parathyroid carcinoma molecular drivers include: quercetin inhibited mTOR phosphorylation confirmed — directly targeting mTORC1-driven cyclin D1 translation and survival signaling relevant to the PI3K/AKT/mTOR pathway in parathyroid carcinoma; quercetin inhibited p-AKT(Ser473) confirmed — targeting AKT kinase activation upstream of mTOR and downstream of PI3K mutations in parathyroid carcinoma; quercetin induced PARP cleavage confirmed — establishing caspase-dependent apoptosis execution in cancer cells; quercetin downregulated cyclin D1 expression confirmed — directly targeting the defining oncogenic driver of parathyroid carcinoma: cyclin D1 is overexpressed in approximately 91% of parathyroid carcinomas due to CDC73/parafibromin inactivating mutations (70-100% of sporadic parathyroid carcinomas) removing parafibromin's H3K9me3-dependent CCND1 transcriptional repression; quercetin downregulated c-Myc expression confirmed — c-Myc is a transcriptional target of both beta-catenin/WNT and NF-kB signaling activated in parathyroid carcinoma through CDC73-loss and WNT pathway mutations; quercetin increased G1 phase cell cycle arrest confirmed — directly counteracting the G1/S checkpoint bypass created by cyclin D1 overexpression and CDK4/6 constitutive activation in parathyroid carcinoma cells; quercetin inhibited GSK3-beta phosphorylation — targeting WNT/beta-catenin pathway activation in parathyroid carcinoma; quercetin reduced c-FLIP (CFLAR) expression — targeting the apoptosis resistance from NF-kB-driven anti-apoptotic gene expression in parathyroid carcinoma.
Curcumin from turmeric inhibits cyclin D1 expression in endocrine tumor cell models through IKK-beta/NF-kB inhibition (NF-kB drives CCND1 transcription) and through direct CDK4/cyclin D1 protein binding — targeting the dominant cyclin D1 overexpression in parathyroid carcinoma; curcumin also inhibits NF-kB, PI3K/AKT, and mTOR in endocrine tumor cell models; curcumin inhibits RANKL-RANK osteoclast activation targeting the pathological bone resorption from autonomous PTH hypersecretion. EGCG from green tea inhibits CDK4/cyclin D1 complex activity in cancer cell models — directly targeting cyclin D1/CDK4-driven RB1 phosphorylation in parathyroid carcinoma; EGCG inhibits mTOR and PI3K/AKT. Resveratrol inhibits cyclin D1 and WNT/beta-catenin in cancer cell models. Allicin from garlic inhibits NF-kB through IKK-beta inhibition targeting NF-kB-driven CCND1 transcription. Sulforaphane from broccoli activates Nrf2/ARE and induces apoptosis in neuroendocrine tumor models; induces p21/CDKN1A targeting CDK4/CDK6 activity.
Nutritional Focus
Nutritional focus in parathyroid carcinoma research is anchored by the CDC73/parafibromin/cyclin D1 axis — the defining oncogenic pathway in ~91% of parathyroid carcinomas — and quercetin from onions with confirmed cyclin D1 targeting activity: quercetin confirmed to downregulate cyclin D1 expression, reduce c-Myc, inhibit p-AKT and mTOR, induce PARP cleavage, and increase G1 phase cell cycle arrest in cancer cell lines (PMC6651418) — directly targeting the CDC73 parafibromin-loss/CCND1 constitutive overexpression that defines parathyroid carcinoma oncogenesis in approximately 91% of cases; quercetin inhibiting WNT/GSK3-beta and reducing c-FLIP targeting apoptosis resistance in parathyroid carcinoma; curcumin from turmeric inhibiting cyclin D1, NF-kB, PI3K/AKT, and mTOR in endocrine tumor cell models targeting the cyclin D1 overexpression and PI3K pathway active in parathyroid carcinoma; curcumin inhibiting RANKL-RANK osteoclast activation targeting the pathological bone resorption from autonomous PTH hypersecretion; EGCG from green tea inhibiting CDK4/cyclin D1 complex activity and mTOR targeting cyclin D1-CDK4 constitutive activity in parathyroid carcinoma; resveratrol inhibiting cyclin D1 and WNT/beta-catenin in cancer cell models; allicin from garlic inhibiting NF-kB through IKK-beta inhibition targeting NF-kB-driven CCND1 transcription; sulforaphane from broccoli inducing Nrf2/ARE and p21/CDKN1A targeting CDK4/CDK6 activity; dietary fiber producing butyrate/SCFAs inhibiting HDAC targeting the epigenetic chromatin remodeling dependent on parafibromin/SUV39H1/H3K9me3 at the CCND1 promoter.
Research Notes
Parathyroid carcinoma epidemiology: rarest endocrine malignancy; 5%); p27 reduced; PGP9.5+. Clinical: serum Ca >14 mg/dL; PTH >5-10x ULN; nephrolithiasis ~60-70%; osteitis fibrosa cystica ~80%; pancreatitis ~15%. Quercetin confirmed (PMC6651418): cyclin D1 downregulated; c-Myc reduced; p-AKT inhibited; mTOR inhibited; PARP cleavage confirmed; G1 arrest confirmed; c-FLIP reduced; GSK3-beta dephosphorylation — all targeting CDC73-loss/CCND1 overexpression and PI3K/mTOR pathways in parathyroid carcinoma.
Notes Visibility
show
Key Foods
Turmeric,Broccoli,Kale,Spinach,Brussels Sprouts,Cauliflower,Garlic,Yellow Onion,Carrot,Tomato,Beetroot,Cabbage,Blueberry,Pomegranate,Grape,Raspberry,Apple,Orange,Lemon,Soybeans,Edamame,Green Lentils,Black Beans,Chickpeas,Brown Rice,Quinoa,Oats,Wild Rice,Black Rice,Walnut,Almond,Brazil Nut,Flaxseed,Pumpkin Seeds,Chia Seeds,Sesame Seeds,Hemp Seeds,Shiitake,Maitake,Lions Mane,Cremini,Portobello,Green Tea,Ginger,Black Pepper,Garlic Powder,Parsley,Rosemary,Oregano, Celery, Leek,Avocado,Artichoke,Radish,Tangerine, Red Onion
Linked Nutrients
vitamin-c,vitamin-e,vitamin-a,vitamin-b9,vitamin-b6,selenium,zinc,magnesium,potassium,iron,quercetin,curcumin,egcg,resveratrol,sulforaphane,beta-carotene,anthocyanins,dietary-fiber,l-theanine,allicin
